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Effect of Vitamin D Supplementation on
Bone Turnover Markers During HIV Pre-
Exposure Prophylaxis Using Tenofovir
Disoproxil Fumarate-Emtricitabine in Men
Who Have Sex with Men
Deepa D. Nanayakkara, Xiaoying Sun, Sheldon Morris, Stan Louie, Kathleen Mulligan, Turner Overton, 
Isaac Asante, Katya Corado, Sonia Jain, and Michael P. DubéI
Abstract
Pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) reduces bone
mineral density in HIV-uninfected men who have sex with men (MSM). We hypothesized that PrEP with TDF-
FTC would increase bone turnover markers (BTMs) at week 24 and that vitamin D supplementation from weeks
24 to 48 would blunt this increase. Participants were from a cohort of 398 MSM and transgender women who
received daily TDF-FTC for PrEP. At week 24, a prospective intervention group initiated vitamin D3 4,000 IU daily.
Concurrent controls were selected from the cohort who took ≤400 IU/day of vitamin D3 matched by age, race,
and body mass index. The primary endpoint was the change in procollagen-I N-terminal propeptide (P1NP)
from weeks 24 to 48. Paired t-tests were used to compare changes in BTMs between intervention and controls.
Among 48 intervention–control pairs, median age was 33 years. At baseline, 68.9% of the intervention group
and 77.3% of controls were vitamin D subcient (≥20 ng/mL, p = .94). P1NP, C-telopeptide, parathyroid hormone
(PTH), and 25-OH vitamin D3 did not increase signifcantly at week 24. P1NP fell by a mean ± SD of −27.6 ± 
49.9 pg/mL from weeks 24 to 48 with vitamin D and −2.5 ± 40.2 pg/mL in controls (p = .01). There were no
signifcant between-group differences in the weeks 24–48 change in C-telopeptide, PTH, or 25-OH vitamin D3.
Vitamin D3 supplementation with 4,000 IU/day resulted in a signifcant reduction in the BTM P1NP compared
with controls, suggesting that this intervention has potential to improve bone health during PrEP.
Introduction
Tenofovir Disoproxil Fumarate-emtricitabine (TDF-FTC; Truvada ; Gilead Sciences) as a daily fxed dose tablet
,
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is approved by the Food and Drug Administration for pre-exposure prophylaxis (PrEP) to prevent HIV acquisition
for persons with increased risk for HIV infection. TDF has well-described toxicities, including greater loss of
bone mineral density (BMD) after antiretroviral therapy (ART) initiation and increased risk of fragility fracture.
 Daily use of TDF-FTC as PrEP is associated with signifcant reduction in BMD, although to a lesser degree
than that seen during initial treatment for HIV.  Hence, long-term PrEP use is potentially associated with
increased fracture risk. Glidden and colleagues showed that mean BMD returns to baseline levels within 12–18
months after discontinuation of TDF-based PrEP.  However, the effects of continued long-term exposure to TDF
during PrEP on bone are not known.
The mechanism by which TDF induces BMD loss is unclear, but it appears to be associated with an increase in
parathyroid hormone (PTH) levels and PTH-controlled calcium and phosphate metabolism.  Some data
suggest that TDF induces a state of functional vitamin D defciency.  Strategies to attenuate or prevent BMD
loss when TDF-containing PrEP is given for prolonged periods of time are needed. Overton et al. reported a
marked reduction in the degree of BMD loss during initial therapy of HIV infection with vitamin D3 4,000 IU/day
and calcium supplementation.  When vitamin D–calcium was coadministered with efavirenz plus TDF-FTC-
based ART for 48 weeks, the amount of BMD loss at the hip measured by dual-energy X-ray absorptiometry
(DEXA) was approximately half that seen with placebo (−1.5% vs. −3.2%, respectively; p < .001).
The objective of our study was to evaluate if supplementation with vitamin D will favorably affect the adverse
changes in bone turnover markers (BTM) that occur after initiation of PrEP with TDF-FTC. Our primary
hypothesis was that supplementation with vitamin D 4,000 IU/day will signifcantly blunt the increase in the
BTM procollagen-I N-terminal propeptide (P1NP) that occurs after initiation of PrEP with TDF-FTC. Secondary
hypotheses included that supplementation with vitamin D 4,000 IU/day will signifcantly blunt the increases in
BTM C-telopeptide (CTX) and PTH that occur after initiation of PrEP with TDF-FTC and increase levels of 25-OH
vitamin D3 compared with control participants not receiving supplementation.
Materials and Methods
Study design
This was a nonrandomized prospective interventional study with retrospectively matched concurrent controls
as a nested substudy of an open-label clinical trial of the effect of a text messaging intervention versus
standard of care on adherence to daily TDF-FTC as PrEP in men who have sex with men (MSM) and
transgender male to female at increased risk for HIV acquisition (CCTG 595; ClinicalTrials.gov Identifer:
NCT01761643). Both the vitamin D intervention group and the matched controls were part of the CCTG 595
clinical trial and were enrolled concurrently into the parent trial. Participation in the substudy was not required
for continued participation in the CCTG 595 trial. The intervention included 48 men matched 1:1 with
concurrent controls based on age (±5 years), race (black vs. nonblack), and body mass index (BMI; ±3 kg/m ).
The intervention group and controls were also matched based on season of enrollment to minimize the effect
of sun exposure on baseline vitamin D levels.
Participants
Study participants were drawn from the men or transgender women at high risk of acquiring HIV infection who
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received daily PrEP with TDF-FTC aged 18 years or older. All study participants were naive to TDF-FTC at the
baseline visit. Participant enrollment to the substudy occurred at the 24-week visit of the CCTG 595 trial.
Eligible participants had substantial ongoing risk of acquisition of HIV and tested negative for HIV infection by
rapid HIV test and confrmed negative by another sensitive method. Laboratory values in the past 30 days
included a calculated creatinine clearance of at least 60 mL/min, liver transaminase levels less than three times
the upper limit of normal, hemoglobin >9 g/dL, absolute neutrophil count >750/mm , and platelet count
>75,000/mm . Exclusion criteria for both groups included current or previous use of bisphosphonate therapy,
current use of vitamin D supplements >400 IU/day, current use of androgenic or growth hormones, history of
nephrolithiasis or fragility fracture, and no previous use of TDF.
Primary and secondary objectives
The primary objective was to compare the change in P1NP levels from week 24 to week 48 among participants
in the intervention group who initiated vitamin D 4,000 IU/day to the change in levels seen in matched controls
taking 400 IU/day or less of vitamin D. The secondary objectives were to (1) compare the change in CTX and
PTH levels from week 24 through week 48 among participants who received vitamin D 4,000 IU/day to the
change in levels seen in matched unsupplemented controls, (2) compare 25-OH vitamin D levels at week 48
among participants who received vitamin D 4,000 IU/day and matched controls, and (3) demonstrate the
change in P1NP, CTX, PTH, and 25-OH vitamin D3 levels from baseline to week 24 in both the intervention group
and controls.
Treatment
Vitamin D3 was supplied as 2,000 IU capsules (NatureMade, Mission Hills, CA) taken as two capsules once
daily, taken from week 24 to week 48. In this study, supplemental calcium was not used because in ACTG 5280
dietary calcium intake among untreated HIV-infected participants was generally adequate.  We thus
anticipated that the largely healthy HIV-uninfected participants in this study would also have adequate dietary
calcium intake.
Clinical and laboratory evaluations
Plasma from participants was collected and stored at entry, 24, and 48 weeks. BTMs were measured after
completion of the study on stored samples. PTH, CTX-1, and P1NP were measured using ELISA-based kits
(Reddot Biotech, Inc., BC, Canada and MyBiosource, Inc., San Diego, CA), respectively. All samples were
analyzed according to manufacturer's recommended procedures, where the replicates were all within
acceptable percentage of coebcient of variation criteria set a priori at <15%. The concentration of 25-OH
vitamin D3 was determined using a validated liquid chromatography–mass spectrometry method. Bone density
measurements were not performed.
To calculate the average daily dietary intake of vitamin D and calcium from food, participants were asked to
recall food items eaten over the last 3 days at the week 36 visit. A calculator adapted from the USDA database
was used to quantify vitamin D and calcium intake.  Tenofovir diphosphate in dried blood spots (DBS) served
as an objective measure of adherence to PrEP.
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Statistical analysis
Forty-four pairs of cases and controls provides 80% power to detect a difference of 20% in the weeks 24–48
change in P1NP between the intervention group and controls, assuming the standard deviation of change is
40% using a paired t-test with a two-sided alpha = 0.05.
Mean changes in BTMs from week 24 to week 48 were compared within groups using a paired t-test. The
Wilcoxon signed-rank test was used for comparison of BTMs at each visit between groups because of the
skewness of the data. Paired t-test was used to compare the change in BTMs from baseline to week 24 for
both groups. Linear regression model assessed the association between change in P1NP and change in
vitamin D levels, adjusting for the week 24 P1NP levels. All analyses were conducted in R (http://cran.r-
project.org), version 3.3.2. Values of p < .05 were considered statistically signifcant.
Results
Forty-eight participants were enrolled to the vitamin D supplementation (intervention) group and compared with
48 matched controls. Baseline characteristics of the groups were similar with regard to age, race, and BMI
(Table 1). All participants were MSM. The number of Hispanic participants was higher in the vitamin D group
than in the control group (33% vs. 17%). Both at baseline and week 24, most study participants had subcient
vitamin D levels (≥ 20 ng/mL; Table 2).  Both the intervention group and controls demonstrated satisfactory
adherence to PrEP, with 87.5% of the intervention group and 85.4% of controls having a DBS tenofovir
diphosphate level of >719 fmol/punch at week 48, indicating at least four weekly doses.  Sixty-fve percent of
the intervention group at week 36 and 64% at week 48 self-reported >90% adherence to the vitamin D
supplement.
Table 1. Patient Characteristics and Adherence to Pre-Exposure Prophylaxis
 Vitamin D supplementation
(n = 48)
Controls (n = 
48)
p
value
Age at entry, median (Q1, Q3) 33.5 (28, 37.5) 33.0 (29,
38.5)
Race, n (%)
 White 26 (55) 25 (53)
 Black 13 (28) 14 (30)  
 Asian 2 (4) 2 (4)  
18
16
*
*
 Multiracial 6 (13) 6 (13)  
Ethnicity, n (%)
 Hispanic 16 (33) 8 (17)  
BMI at week 24, kg/m , median
(Q1, Q3)
25.6 (24.1, 27.5) 26.0 (23.3,
28.4)
Treatment assignment in parent trial, n (%)
 Standard of care arm 25 (52) 22 (46) .68
 Text messaging arm 23 (48) 26 (54)  
Dried blood spot tenofovir diphosphate fmol/punch, median (Q1, Q3)
 Week 12 1,165 (909, 1,393) 1,148 (905,
1,408)
.39
 Week 48 1,068 (935, 1,388) 1,110 (859,
1,475)
.87
Percent with tenofovir diphosphate >719 fmol/punch, %
 Week 12 91.7 87.5 .74
 Week 48 87.5 85.4 >.99
p value by paired t-test. p values not reported for age, race, and BMI because there were matching criteria.
BMI, body mass index; Q1, frst quartile; Q3, third quartile.
Table 2. Vitamin D Status
2 *
*
 Vitamin D supplementation Controls Total p value
Baseline
 Su_cient 31 (68.89) 33 (73.33) 64 (71.11) .94
 Insu_cient 10 (22.22) 8 (17.78) 18 (20)  
 De`cient 4 (8.89) 4 (8.89) 8 (8.89)  
Week 24
 Su_cient 29 (60.42) 39 (81.25) 78 (70.83) .093
 Insu_cient 15 (31.25) 8 (16.67) 23 (23.96)  
 De`cient 4 (8.33) 1 (2.08) 5 (5.21)  
Week 48
 Su_cient 37 (77.08) 32 (66.67) 69 (71.88) .388
 Insu_cient 10 (20.83) 12 (25) 22 (22.92)  
 De`cient 1 (2.08) 4 (8.33) 5 (5.21)  
Vitamin D subcient was considered 25-OH vitamin D3 level ≥20 ng/mL, insubcient 12 to <20 ng/mL, and
defcient <12 ng/mL. p value by paired t-test.
Values are given as n (%).
P1NP level was unexpectedly higher among the intervention group than controls at week 24 (Table 3). P1NP
decreased by a mean of −27.6 ± 49.9 pg/mL from week 24 to 48 with vitamin D supplementation. The P1NP
level decreased only −2.5 ± 40.2 pg/mL in controls (Table 3 and Fig. 1). The mean change in P1NP from week
24 to week 48 between groups was signifcantly different (p = .011). The percent reduction in P1NP level from
week 24 to 48 was also greater with vitamin D supplementation (−14.6% ± 52.5%) than in controls (20.7% ± 
67.3%, p = .006). In a multivariable linear regression model controlling for week 24 P1NP levels, greater increase
in 25-OH vitamin D3 between weeks 24 and 48 was associated with greater decrease in P1NP between weeks
24 and 48 (coebcient estimate = −0.59, p = .006). Post hoc mixed model analysis of the absolute change in
P1NP from week 24 to 48 showed no statistically signifcant difference between the groups after adjusting for
the week 24 P1NP levels (p = .23).
FIG. 1.  Change in P1NP level from week 24 to 48. P1NP levels were higher among the vitamin D
supplementation group (cases) compared with controls at week 24. P1NP fell by a mean of −27.6 ± 49.9 pg/mL
from week 24 to 48 with vitamin D 4,000 IU/day supplementation and by −2.5 ± 40.2 in controls (p = .011, paired
t-test). The paired Wilcoxon signed-rank test was used for comparison at each time point because of the
skewness of the data. p = .14 at baseline; p = .003 at week 24; p = .35 at week 48. P1NP, procollagen-I N-
terminal propeptide. Color images are available online.
Table 3. Bone Turnover Markers
 P1NP pg/mL p value CTX ng/mL p value
Baseline, median (IQR)
 Vitamin D 68.1 (37.6–137) .137 1.3 (0.6–2.5) .258a
 Controls 44.5 (34.6–74.1)  1.4 (0.7–2.8)  
Week 24, median (IQR)
 Vitamin D 75.3 (41.6–133) .003 1.1 (0.6–2.1) .023
 Controls 43.4 (26.8–67.2)  1.5 (0.6–3.1)  
Week 48, median (IQR)
 Vitamin D 54.3 (28.0–99.0) .349 0.8 (0.6–1.5) .003
 Controls 48.6 (31.2–72.5)  1.35 (0.7–4.2)  
Mean (±SD) change from week 24 to 48
 Vitamin D −27.6 ± 49.9 .011 0.03 ± 1.12 .398
 Controls −2.5 ± 40.2  0.29 ± 2.10  
p value by paired Wilcoxon signed-rank test.
p value by paired t-test.
P1NP, procollagen-I N-terminal propeptide; CTX, C-telopeptide; IQR, interquartile range.
There was no signifcant change in P1NP, CTX, PTH, or 25-OH vitamin D3 levels from baseline to week 24
(Tables 3 and 4). Levels of 25-OH vitamin D3 increased from week 24 to 48 among the intervention group
receiving 4,000 IU of vitamin D3 daily, but this was not statistically signifcant (within-group p = .065). The
change in P1NP levels observed from baseline to week 24 did not differ by adherence to PrEP assessed at
week 12 (data not shown).
Table 4. Parathyroid Hormone and 25-OH Vitamin D  Levels
 PTH pg/mL p value 25-OH vitamin D  ng/mL p value
Baseline, median (IQR)
a
a
b
a
b
3
3
 Vitamin D 165.2 (120.9–238) .524 25.7 (17.6–31.9) .769
 Controls 143.9 (95.3–224.4)  29 (19.7–37)  
Week 24, median (IQR)
 Vitamin D 165.2 (126.9–214.9) .354 23.6 (17.2–29.8) .621
 Controls 164.5 (92.4–216.7)  26.2 (21.7–30.4)  
Week 48, median (IQR)
 Vitamin D 183.5 (149.7–299.1) .358 31.1 (20.8–38.7) .055
 Controls 190.5 (114.9–347.8)  35.4 (26.1–49.7)  
Mean change from week 24 to 48
 Vitamin D 57.3 ± 128.9 .206 4.4 ± 16.2 .098
 Controls 108.4 ± 210.5  −0.9 ± 13.7  
Paired t-test was used.
PTH, parathyroid hormone.
Discussion
Contrary to our expectations, there were no changes in BTMs or levels of PTH over the initial 24 weeks of PrEP
with daily TDF-FTC and a high degree of adherence assessed by DBS TDF-DP levels. However, supporting our
primary hypothesis, the addition of 4,000 IU/day of vitamin D3 at week 24 to week 48 of PrEP resulted in a
signifcant decrease in P1NP levels compared with unsupplemented controls taking ≤400 IU/day. This
suggests that vitamin D supplementation has the potential to blunt the decreases in BMD associated with daily
TDF-FTC PrEP.
The fxed-dose combination of TDF-FTC has proven to be a highly effective PrEP agent.  Because PrEP
involves long-term administration of drugs to generally healthy individuals, it is particularly important to monitor
drug safety. The mechanism by which TDF induces BMD loss is unclear. Data suggest that TDF induces a state
of functional vitamin D defciency.  Havens et al. observed increased vitamin D binding protein and lower
19–21
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free 1,25-OH(2)D levels in individuals with higher plasma tenofovir concentrations, which may explain TDF-
associated increased PTH levels. A recent study reported that PTH-vitamin D-fbroblast growth factor 23
(FGF23), which causes phosphate wasting, is a primary contributor to TDF-associated decrease in BMD.
Moreover, the level of vitamin D binding protein has been shown to increase upon initiation of TDF-based
therapy, which may be associated with bone loss.  Thus, when TDF-containing PrEP is used for prolonged
periods of time, approaches to attenuate or prevent BMD loss are needed.
The baseline vitamin D status inuuences the effect of TDF on BMD, with vitamin D subciency showing a
protective outcome.  The use of TDF and the level of 25-OH vitamin D level have both been shown to
independently associate with PTH levels. In a study that examined the effect of vitamin D status and TDF use
on PTH levels among HIV-positive patients receiving combination ART, higher PTH values were more commonly
seen among TDF users with suboptimal vitamin D status compared with nonusers.  The underlying etiology is
not completely understood; however. Bech et al. reported that 1-year treatment for vitamin and/or calcium
defciency improved vitamin D levels, decreased serum PTH, and improved calcium balance and BMD.  A
recent randomized double-blind trial evaluated BTMs and BMD with supplementation of three different vitamin
D3 doses in HIV-infected youth with baseline serum 25-OH vitamin D concentrations <30 ng/mL.  They found
that high-dose vitamin D supplementation with 120,000 IU/month given over 12 months decreases BTMs.
Furthermore, Havens et al. reported that vitamin D supplementation with 50,000 IU/month in youth aged 16–24
years with HIV taking TDF had increased lumbar spine BMD through 48 weeks, independent of baseline vitamin
D status.
Generally, vitamin D supplementation is well-tolerated and safe. The dose of vitamin D (4,000 IU/day) in our
study carries little risk. The present U.S. Dietary Reference Intake of 2,000 IU/day is considered to be below the
actual physiologic requirements.  The Institutes of Medicine guideline considered 4,000 IU/day to be the
safe upper limit for daily intake for adults.  Several studies have demonstrated the safety of chronic daily
administration of 4,000 IU of vitamin D.
Our study has several limitations. The P1NP level was unexpectedly higher among the intervention group
compared with controls at week 24, before initiation of vitamin D supplementation. It is possible that the lower
P1NP levels at week 24 among the controls were because of greater vitamin D intake by this group, as
compared with the individuals who agreed to vitamin D supplementation starting at week 24. However, week 24
vitamin D use, as assessed by self-report, was not different between groups. The post hoc analyses that tried to
explore the impact of the between-group difference in week 24 P1NP levels (multivariable linear regression
examining change in P1NP and the vitamin D with adjustment of week 24 P1NP and mixed model adjusting for
week 24 P1NP) provided conuicting results. Nonetheless, there was a positive result in our prespecifed primary
analysis comparing the week 24 to 48 change in P1NP between groups.
A placebo-controlled study of vitamin D supplementation would have been optimal, as compared with using a
matched concurrent control group. However, fndings of this study provide the rationale for a large-scale
randomized, placebo-controlled study evaluating the effect of vitamin D supplementation on BMD among TDF-
FTC PrEP users. Because of dibculties and expense of performing DEXA in this clinical trial, we used
biochemical BTMs in this pilot study. P1NP is a marker that is specifc to bone formation and CTX is a marker
specifc to bone resorption. In ACTG 5280, there was a good correlation between change in BMD by DEXA and
changes in BTMs, making BTMs a plausible surrogate marker of BMD changes. The percentage change of
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P1NP at week 48 correlated with the percentage change in total hip BMD (r = −0.32, p = .01) and the change in
lumbar spine BMD (r = −0.37, p = .002) (Overton ET, unpublished data). Measurement of circulating BTMs can
be confounded by within-patient and biologic variability (age, gender, BMI, and circadian variation). In this study
however, we matched for age and BMI, and all were male at birth.
Adherence to vitamin D in this study was high by self report, and measured adherence to PrEP was also high
and unaffected by the daily use of vitamin D. However, we observed only a nonsignifcant trend toward
increased 25-OH vitamin D3 levels from week 24 to 48 with 4,000 IU/day, suggesting a possible contribution of
unreported suboptimal adherence. A majority of our study participants had subcient vitamin D levels at
baseline and at week 24, thus there may have been limited room for improvement with supplementation. Sunny
southern California weather may have contributed to this phenomenon. However, additional vitamin D still has
the potential to provide beneft, as was observed in patients with HIV initiating TDF-containing ART in ACTG
5280, where baseline vitamin D status did not inuuence the effect of vitamin D supplementation on BMD and
this beneft occurred at all vitamin D levels.  We did not observe a differential effect on P1NP levels based on
baseline 25-OH vitamin D3 levels in our study.
Conclusion
Our study demonstrated that daily PrEP with Truvada in MSM did not adversely affect the BTMs P1NP and CTX,
nor did it affect levels of PTH and vitamin D over the initial 24 weeks. The addition of vitamin D3 4,000 IU/day
beginning at week 24 resulted in a signifcant decrease in P1NP levels at week 48 compared with matched
controls taking ≤400 IU/day. Hence, vitamin D3 4,000 IU/day in MSM taking Truvada as PrEP should be further
studied as an intervention to improve bone health in this population.
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